House Panel Advances Bill to Expand FDA Use of Animal Drug Testing Methods
The House Energy & Commerce Committee’s Health Subcommittee has advanced bipartisan legislation aimed at accelerating the FDA’s implementation of the FDA Modernization Act 2.0, a landmark law intended to expand the use of alternatives to animal testing in drug development. The bill, led by former Health Subcommittee Chair Rep. Buddy Carter (R-GA), now moves to full committee consideration and reflects growing congressional interest in modernizing preclinical research and regulatory science.
The FDA Modernization Act 2.0, signed into law in 2022, removed longstanding federal requirements that experimental drugs be tested in animals before human clinical trials could begin. Instead, the law authorized the FDA to consider “new approach methodologies” (NAMs), including organ-on-chip systems, advanced computer modeling, artificial intelligence-driven simulations, and human cell-based assays, as potential alternatives to traditional animal studies.
While the original legislation created the legal framework for using these newer technologies, supporters of the current bill argue that implementation at the FDA has been slower and less consistent than anticipated. The new legislation would require the agency to more fully integrate these alternative methods into its drug review and development processes, including clearer guidance for industry and greater coordination across FDA centers.
The implications for the biotechnology and pharmaceutical sectors could be significant. Proponents contend that NAMs have the potential to reduce drug development costs, shorten timelines, improve predictive accuracy for human safety and efficacy, and decrease reliance on animal testing. Many researchers believe these technologies may better replicate human biology than traditional animal models, particularly in areas such as oncology, neurological disease, and rare disorders.
For Michigan’s life sciences ecosystem, the legislation could create new opportunities for companies and academic institutions developing advanced in vitro models, AI-enabled drug discovery platforms, and precision medicine technologies. The growing emphasis on alternative testing methodologies is also expected to drive investment in bioengineering, computational biology, and translational research infrastructure.
At the same time, some stakeholders caution that broader adoption of NAMs will require robust scientific validation and clear regulatory standards to ensure patient safety and maintain confidence in the drug approval process. As the FDA continues to evaluate how best to incorporate these emerging technologies, the legislation signals continued momentum toward a more modern, technology-driven approach to biomedical innovation and regulatory science.
